What topics does this cannabis study cover?

This study covers research on: CBD, Cancer.

Where was this research published?

Published in Nanotechnology, science and applications on September 23, 2026.

CBD–epirubicin carrier reduced ovarian cancer cell viability in vitro

Q: What did this research study find?

The *hydroxyapatite* carrier successfully incorporated both *CBD* and epirubicin and was reported to have excellent colloidal stability.

Functionalized Colloidal Hydroxyapatite for Combined Delivery of Cannabidiol and Epirubicin: Characterization, Biomimetic Membrane Interaction, and Cytotoxicity Studies.

Nanotechnology, science and applications • September 23, 2026 • Relevant

🤖

AI Summary

This study asked whether colloidal hydroxyapatite could carry CBD and the chemotherapy drug epirubicin together and affect ovarian cancer cells. Researchers characterized the carrier, examined its release and interactions with model cell membranes, and tested cell viability using an MTS assay. The abstract reports successful incorporation of both compounds and good colloidal stability; epirubicin loading was 0.0605 mg per 1 mg of carrier.

In laboratory tests, the functionalized carrier showed stronger interactions with model lipid membranes and significantly reduced ovarian cancer cell viability compared with free drug and the carrier without the drugs. Release was time-dependent, reaching approximately 2 μg/mL after 24 hours. These are cell and model-membrane findings, not evidence of benefit in people. This abstract-based summary cannot establish safety, targeted delivery in a living organism, or effectiveness as an ovarian cancer treatment; it does not report sample sizes or detailed effect sizes.

💡 Key Findings

The hydroxyapatite carrier successfully incorporated both CBD and epirubicin and was reported to have excellent colloidal stability.

High

90%

In cell testing, the functionalized carrier significantly reduced ovarian cancer cell viability compared with free drug and the non-functionalized carrier.

Good

70%

Drug release was time-dependent, reaching approximately 2 μg/mL after 24 hours in phosphate-buffered saline.

High

90%

The carrier showed enhanced affinity for model lipid membranes, but these laboratory findings do not establish targeted delivery or treatment effectiveness in people.

High

80%

📄 Original Abstract

INTRODUCTION: A stable colloidal hydroxyapatite (cHAp) platform was successfully developed for the co-delivery of cannabidiol (CBD), a natural bioactive compound, and epirubicin (EPI), a chemotherapeutic agent, to enhance cytotoxicity against ovarian cancer cells. METHODS: Colloidal cHAp was synthesized and functionalized with CBD and EPI to obtain a multifunctional drug delivery system. The resulting composite was characterized using high-performance liquid chromatography, UV-Vis spectrometry, transmission and scanning electron microscopies, Fourier-transform infrared spectroscopy, Turbiscan analysis, and differential scanning calorimetry. Drug release in phosphate-buffered saline (PBS, pH 7) was evaluated by differential pulse voltammetry. Interactions with model lipid monolayers mimicking healthy and cancerous cell membranes were investigated using the Langmuir technique, and cytotoxicity was assessed by MTS assays. RESULTS: The successful incorporation of both biologically active compounds into the cHAp carrier and its excellent colloidal stability were confirmed. The epirubicin loading content was 0.0605 mg per 1 mg of cHAp. Drug release followed a time-dependent profile, reaching approximately 2 μg mL-1 after 24 h. The functionalized cHAp systems exhibited enhanced affinity toward model lipid monolayers and significantly reduced the viability of ovarian cancer cells compared with the free drug and non-functionalized carrier. CONCLUSION: The developed cHAp platform provides a stable and multifunctional carrier for the co-delivery of CBD and epirubicin. Its favorable physicochemical properties, enhanced membrane interactions, and improved anticancer activity highlight its potential as a promising nanocarrier for targeted ovarian cancer therapy.

Paper Type

📄 Research

Publication

Journal: Nanotechnology, science and applications
Published: September 23, 2026
PMID: 42807438
DOI: 10.2147/NSA.S617933

Authors (11)

Paulina Końska Faculty of Chemistry, University of Warsaw, Warsaw, Poland.
Magdalena Osial Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland.
Daria Paulina Kępińska Biotech Evolution, Łomianki, Poland.
Jan Taudul Faculty of Chemistry, University of Warsaw, Warsaw, Poland.
Sławomir Wilczewski Faculty of Chemical Technology and Engineering, Bydgoszcz University of Science and Technology, Bydgoszcz, Poland.
+6 more authors